|
Re: Epizyme market cap $750 mil USd
|
3
|
Zenith Epigenetics
|
Jun 18, 2017 08:47AM
|
|
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
|
6
|
Resverlogix Corp.
|
Jul 10, 2017 07:53AM
|
|
Re: Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
|
4
|
Resverlogix Corp.
|
Jul 10, 2017 08:37AM
|
|
Re: FDA approves BetOnMace in US
|
2
|
Resverlogix Corp.
|
Jul 25, 2017 09:07AM
|
|
Re: Debt and 28 August
|
6
|
Resverlogix Corp.
|
Jul 28, 2017 09:40AM
|
|
Re: Debt and 28 August
|
1
|
Resverlogix Corp.
|
Jul 28, 2017 11:20AM
|
|
Re: Debt and 28 August
|
3
|
Resverlogix Corp.
|
Aug 03, 2017 11:02AM
|
|
Resverlogix (RVX) Reports Fiscal Year 2017 Results
|
5
|
Resverlogix Corp.
|
Aug 15, 2017 07:14AM
|
|
Zack's Research Report by Vandermosten dated Aug 2nd, 2017
|
3
|
Resverlogix Corp.
|
Aug 15, 2017 07:22AM
|
|
Re: Fuzyjr
|
4
|
Resverlogix Corp.
|
Aug 22, 2017 12:17PM
|
|
Re: Fuzyjr
|
|
Resverlogix Corp.
|
Aug 23, 2017 08:48AM
|
|
Made for TV Movie
|
3
|
Resverlogix Corp.
|
Aug 28, 2017 08:02AM
|
|
Re: Made for TV Movie
|
3
|
Resverlogix Corp.
|
Aug 28, 2017 08:45AM
|
|
Successful CANTOS Inflammation Trial Supports Rationale for Resverlogix' Ongoing BETonMACE Trial
|
6
|
Resverlogix Corp.
|
Aug 29, 2017 01:03PM
|
|
Re: The MD@A for the period ending July 31, 2017
|
4
|
Resverlogix Corp.
|
Sep 14, 2017 08:02AM
|
|
Re: The MD@A for the period ending July 31, 2017
|
2
|
Resverlogix Corp.
|
Sep 14, 2017 11:02AM
|
|
Re: The MD@A for the period ending July 31, 2017
|
5
|
Resverlogix Corp.
|
Sep 15, 2017 08:50AM
|
|
Re: Possibile deals for both RVX and Zenith
|
2
|
Resverlogix Corp.
|
Oct 17, 2017 09:52AM
|
|
Re: A few things
|
2
|
Resverlogix Corp.
|
Oct 17, 2017 11:22AM
|
|
Resverlogix Seeking Partnership for Potential Therapeutic for HIV-1
|
4
|
Resverlogix Corp.
|
Jun 07, 2018 07:57AM
|
